Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%
MO

Moderna, Inc. (MRNA)

NASDAQ • Healthcare

$192.57
-$10.89 (-5.4%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$186.55
Day Range$184.58 - $196.83
Avg. Volume (3M)14.7M
Market Cap$76.4B
52 Week Range
$22.28$208.9
Next EarningsIn 35 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$145M100%
Gross Profitminus cost of goods$52M36%

Fundamentals & Financials

Revenue (TTM)
$2.2B
Net Income (TTM)
-$3.1B
EPS (TTM)
-$7.98
ROA (TTM)
-28.75%
Current Ratio
2.29
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+16.9%Q1 2026-$2.11
+23.6%Q2 2026-$3.4
+3.0%Q3 2026-$1.97
Next

Nov 5

in 35 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +3.0%

Moderna’s EPS of -$1.97 topped the -$2.03 estimate, +3.0%, as revenue rose 2.1% to about $145.0 million in the second fiscal quarter of 2026, reported July 31. Revenue moved up from about $142.0 million a year ago, while operating income remained negative at about $815.0 million and net income came in as a loss of about $782.0 million, up 5.2% from a loss of about $825.0 million a year ago. The company also repurchased about $2.0 million of stock during the period. Consensus for the next period calls for EPS of -$1.38 on revenue of $872.9 million.

View full earnings history

About Moderna, Inc.

Moderna, Inc. develops and commercializes messenger RNA medicines and vaccines as a biotechnology company in healthcare, with $1.9 billion in revenue in FY2025. Listed on the NASDAQ Global Select Market under MRNA, the company applies its mRNA platform to preventive vaccines as well as therapeutic programs across infectious disease, oncology, and other treatment categories.

Name
Moderna, Inc.
CEO
Stéphane Bancel
Website
www.modernatx.com
Industry
Healthcare
Year Founded
2010
Employees
4,700

Today's Snapshot

AI-generated

MRNA closed 5.3% below yesterday's close, in line with a weaker sector. Citi analysts downgraded Moderna to Sell over valuation concerns.

Trading Volume

Above 10d avg 17.9M

20M

vs S&P 500 Today

Strong Underperformance

-5.54%

Updated: September 30, 2026 at 20:20 UTC

MRNA Headlines

Cancer vaccine data lifts biotech shares

September 13, 2026

3 min read

Moderna–Merck mRNA melanoma trial succeeds

August 22, 2026

3 min read

Arbutus plans US$230m share tender offer

August 21, 2026

3 min read

Moderna, Merck report positive melanoma trial

August 21, 2026

3 min read
View All News

Technical Indicators

6 Buy1 Neutral1 Sell
MRNA near 192.57 shows strong bullish characteristics with robust momentum and a powerful trend; MACD and short-term momentum are strongly positive and ADX is well into strong-trend territory. The price sits comfortably above short-, medium- and long-term moving averages, and on-balance volume confirms sustained buying pressure, though average true range signals elevated volatility. A nearby pivot sits above the market, but overall technical breadth favors the upside. Technical takeaway: Strong buy.
All signals
  • EMA (5 indicators)$75.76 - $184.28
    Buy
  • RSI (14)68.33
    Neutral
  • Stochastic %K (14, 3, 3)87.84
    Sell
  • MACD Level (12, 26)21.74
    Buy

Peers & Related Assets

RVMDRevolution Medicines, Inc.
$205.26+0.4%
EXELExelixis, Inc.
$58.41-0.4%
JAZZJazz Pharmaceuticals plc
$231.52-0.4%
HALOHalozyme Therapeutics, Inc.
$110.4-1.0%
BBIOBridgeBio Pharma, Inc.
$65.8-0.3%
MDGLMadrigal Pharmaceuticals, Inc.
$503.96-1.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.